OrbiMed's modest sell-down at $11.71, while small in absolute size, signals reduced conviction at current levels. Monitor for further sales or a potential exit—the activist remains passive with no stated catalyst. The stock may face overhang from the remaining 5.8% position.
Price Chart
Executive Summary
OrbiMed Advisors filed Amendment No. 2 to its Schedule 13D for ArriVent BioPharma (AVBP), reporting a reduction in beneficial ownership by more than 1% following the sale of 151,366 shares at $11.71 on October 6, 2026. The filing states no change in purpose—the investment remains passive—and the aggregate stake held by OrbiMed entities is now 2,875,962 shares, or 5.8% of outstanding shares.
Key Financial Metrics
Key Facts
- OrbiMed sold 151,366 shares total (75,683 from OPI VIII and 75,683 from OAP IV) at $11.71 per share on October 6, 2026.
- Aggregate beneficial ownership decreased to 2,875,962 shares, or 5.8% of outstanding shares (down from a prior level above 6.8%).
- The filing states no change in purpose—the investment remains passive with no plans for control, board changes, or extraordinary transactions.
- OrbiMed retains demand and piggyback registration rights under the Amended and Restated Investors' Rights Agreement.
Financial Impact
Sale of 151,366 shares at $11.71 for gross proceeds of approximately $1.77 million; stake reduction of ~1% of outstanding shares.
Risk Factors
- Further share sales by OrbiMed could pressure the stock.
- Lack of activist catalyst or strategic plan leaves the stock without a near-term positive driver.
- The sale occurred near the stock's current price, suggesting limited near-term upside conviction from the largest holder.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13D/A Filing (Primary) | 0000947871-26-000931 |
| Document: 0000947871-26-000931-index-headers.html | 0000947871-26-000931 |
| Document: 0000947871-26-000931-index.html | 0000947871-26-000931 |
| Document: 0000947871-26-000931.txt | 0000947871-26-000931 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 8-K | $15.36 $15.40 | ▲ +0.26% | ▼ −0.30% | $15.40 (+0.26%) |
Oct 25, 2026 2d ago | Press Release | $15.36 $15.40 | ▲ +0.26% | ▼ −0.30% | $15.40 (+0.26%) |
Oct 23, 2026 4d ago | Press Release | $15.36 $15.40 | ▲ +0.26% | ▼ −0.30% | $15.40 (+0.26%) |
Oct 19, 2026 8d ago | 8-K | $17.94 $18.85 | ▲ +5.07% | ▲ +4.74% | $15.40 (−14.16%) |
Oct 13, 2026 14d ago | SC 13G | $16.20 $16.79 | ▲ +3.64% | ▲ +3.36% | $15.40 (−4.94%) |
Oct 13, 2026 14d ago | 8-K | $16.09 $16.20 | ▲ +0.68% | ▲ +1.76% | $15.40 (−4.29%) |
Oct 8, 2026 19d ago | SC 13D/A | $16.73 $16.46 | ▲ +1.61% | ▲ +1.55% | $15.40 (+7.95%) |
Oct 6, 2026 21d ago | 8-K | $15.09 $16.89 | ▼ −11.93% | ▼ −12.17% | $15.40 (−2.05%) |
Aug 12, 2026 10w ago | Press Release | $30.00 $29.51 | ▲ +1.63% | ▲ +1.44% | $15.40 (+48.67%) |
Jun 11, 2026 19w ago | Institutional Cluster | $30.54 $30.30 | ▼ −0.79% | ▼ −2.55% | $15.40 (−49.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers